TransMedics, founded in Andover, Massachusetts, is dedicated to revolutionizing organ transplantation through advanced technology and clinical service solutions. Their core mission is to improve clinical outcomes and increase the volume of heart and lung transplants while reducing learning curves for medical professionals. The company’s flagship product, the Organ Care System (OCS™), is the only FDA-approved technology in the U.S. for lung, heart, and liver transplantation, offering a new standard of care by mitigating the limitations of traditional cold storage.

Notable figures associated with TransMedics include its founder and key investors who have significantly contributed to its growth. The company has achieved several milestones, including FDA PMA approval for the OCS™ DCD Heart indication and establishing the National OCS™ Program (NOP) to overcome time and distance barriers in organ transportation. TransMedics has made a substantial impact on the transplant community by enhancing the viability and success rates of organ transplants, thereby saving more lives and setting new industry standards.